Wong Jessie J, Suttiratana Sakinah C, Lal Rayhan A, Lum John W, Lanning Monica S, Dunlap Adrienne, Arbiter Brandon, Hanes Sarah J, Bailey Ryan J, Hood Korey K, Naranjo Diana
Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Diabetes Technol Ther. 2022 Apr;24(4):241-248. doi: 10.1089/dia.2021.0362.
Loop is an open-source automated insulin dosing system that allows users unrivaled control over system settings that affect future glucose prediction. Thousands use Loop, but little is known about those who discontinue. In a large observational study, 874 Loop participants completed surveys and provided glycemic data, 46 (5.3%) of those self-identified as discontinuing Loop use during the observation window, 45 completed a discontinued use survey, 22 provided system settings data, and 19 participated in semistructured interviews about their discontinuation. Qualitative data were transcribed, coded, and analyzed. Older age and not trusting Loop were associated with discontinued use, although no other demographic or clinical characteristics were significant correlates. The most endorsed reasons were "I decided to try something else" (27.8%) followed by "It just didn't help as much as I thought it would" (22.2%). Qualitative analyses revealed prominent themes centered upon mental and emotional burden and adjusting settings. Other reasons for discontinued use included fear of disapproval of Loop use from diabetes provider, barriers to acquiring component devices, a desire to try new/different technologies, concerns that Loop could not accommodate specific exercise or low insulin dose regimens, and worry about Loop use during pregnancy. It was noted that burdens might be alleviated by enhanced technical assistance and expert guidance. Although the majority of individuals in the Loop observational study continued use, those who discontinued reported similar challenges. Technical support and education specific to setting calculations could expand Loop benefits, alleviate burden, and support sustained use among new Loop users. Clinical Trial Registration: clinicaltrials.gov (NCT03838900).
Loop是一个开源的自动胰岛素给药系统,它能让用户对影响未来血糖预测的系统设置进行无与伦比的控制。数千人使用Loop,但对于那些停止使用的人却知之甚少。在一项大型观察性研究中,874名Loop参与者完成了调查并提供了血糖数据,其中46人(5.3%)在观察期内自行认定停止使用Loop,45人完成了停用调查,22人提供了系统设置数据,19人参与了关于停用原因的半结构化访谈。定性数据被转录、编码和分析。年龄较大以及不信任Loop与停用有关,不过没有其他人口统计学或临床特征是显著的相关因素。最常被提及的原因是“我决定尝试其他方法”(27.8%),其次是“它并没有像我想象的那样有帮助”(22.2%)。定性分析揭示了围绕精神和情感负担以及调整设置的突出主题。其他停用原因包括担心糖尿病医护人员不认可使用Loop、获取组件设备存在障碍、想要尝试新的/不同的技术、担心Loop无法适应特定的运动或低胰岛素剂量方案以及担心孕期使用Loop。研究指出,加强技术援助和专家指导可能会减轻负担。尽管Loop观察性研究中的大多数人继续使用,但那些停止使用的人也报告了类似的挑战。针对设置计算的技术支持和教育可以扩大Loop的益处、减轻负担并支持新Loop用户持续使用。临床试验注册:clinicaltrials.gov(NCT03838900)。